HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $16

Benzinga · 23h ago
HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $38 to $16.